Bioinspired Anti‐VEGF Peptide Nanoparticle with Immune Regulating and Corneal Epithelium Penetration Capability for Corneal Neovascularization Therapy

Why It Matters

Corneal neovascularization currently lacks effective, penetrative therapies; this platform simultaneously tackles drug delivery barriers and inflammation, promising a new therapeutic class for vision‑threatening eye disease.

Key Takeaways

• Nanoparticle penetrates 300 µm into corneal tissue.
• Retains on ocular surface for ~70 minutes.
• Scavenges 60% of excess reactive oxygen species.
• Inhibits corneal angiogenesis by ~60% in 3D model.
• Modulates macrophages, reducing pro‑inflammatory polarization.

Pulse Analysis

Corneal neovascularization (CorNV) remains a leading cause of vision loss, largely because the cornea’s tight epithelial barrier prevents most therapeutics from reaching the stromal vasculature. Conventional anti‑VEGF eye drops suffer from rapid clearance, while intravitreal injections carry infection risks and limited penetration. The unmet clinical need has spurred interest in nanocarriers that can both breach the epithelium and modulate the inflammatory milieu that fuels abnormal vessel growth.

The newly reported nanoparticle leverages a bioinspired assembly: a VEGF‑blocking peptide is stabilized with Cu²⁺ ions, then functionalized with a reactive‑oxygen‑species (ROS) scavenger and a cell‑penetrating peptide. This multi‑modal design yields a 70‑minute ocular residence time and a 300‑micron penetration depth—metrics that far exceed typical ophthalmic formulations. In vitro, the particle neutralizes roughly 60 % of ROS and curtails angiogenic sprouting by a comparable margin, while also shifting macrophage polarization away from a pro‑inflammatory phenotype. Animal studies confirm these effects, showing clear reductions in neovascular outgrowth and inflammatory marker expression.

If translated to the clinic, this technology could reshape the market for ocular anti‑angiogenic drugs, which currently relies on frequent injections and steroid regimens. Its dual action—targeted VEGF inhibition plus oxidative‑stress mitigation—offers a broader therapeutic window and may reduce dosing frequency, improving patient adherence. Regulatory pathways for peptide‑based nanomedicines are becoming clearer, and the platform’s modularity suggests it could be adapted for other oxidative‑stress‑driven eye conditions, such as diabetic retinopathy or age‑related macular degeneration. Continued pre‑clinical validation and scalable manufacturing will be critical to unlock its commercial potential.